Literature DB >> 6454382

Piperacillin pharmacokinetics in subjects with chronic renal failure.

M I Thompson, M E Russo, J M Matsen, E Atkin-Thor.   

Abstract

The pharmacokinetic parameters of piperacillin sodium were studied in eight volunteer subjects with chronic renal failure. Subjects were given a single 30-min intravenous infusion of 70 mg/kg (lean body weight) on their off-dialysis day. Blood was drawn from the contralateral arm at 15 and 30 min and 1, 3, 6, 9, and 12 h from the start of the infusion. Kinetic parameters were determined during the elimination phase with a one-compartment open model for linear kinetics. The following pharmacokinetic parameters (mean +/- standard deviation) were determined for the eight subjects: elimination half-life = 3.33 +/- 0.99 h, elimination rate constant = 0.22 +/- 0.06 h-1, apparent volume of distribution = 0.18 +/- 0.05 liters per kg, and total body clearance = 0.041 +/- 0.019 liters per kg/h. The mean peak serum concentration was 372 +/- 125 microgram/ml, and mean trough at 12 h was 39 +/- 27 microgram/ml. A dose of 70 mg/kg (lean body weight) or a dose of 4 g appears to provide adequate serum concentrations against susceptible organisms for a 12-h interval. No adverse reactions were noted in any subject throughout the study.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454382      PMCID: PMC181452          DOI: 10.1128/AAC.19.3.450

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Piperacillin and carbenicillin; a collaborative in vitro comparison against 10,838 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; E H Gerlach; T L Gavan
Journal:  Cleve Clin Q       Date:  1979

2.  Carbenicillin therapy in patients with normal and impaired renal function.

Authors:  D L Latos; C S Bryan; W J Stone
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

3.  Carbenicillin administration in patients with severe renal failure.

Authors:  J B Eastwood; J R Curtis
Journal:  Br Med J       Date:  1968-02-24

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

Authors:  E L Francke; G B Appel; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

6.  Pharmacokinetics of ticarcillin in patients with abnormal renal function.

Authors:  M F Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

7.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

9.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

10.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

View more
  13 in total

1.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure.

Authors:  W-T Huang; Y-J Hsu; P-L Chu; S-H Lin
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

3.  Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.

Authors:  Tobias Rachow; Verena Schlüter; Sibylle Bremer-Streck; Udo Lindig; Sebastian Scholl; Peter Schlattmann; Michael Kiehntopf; Andreas Hochhaus; Marie von Lilienfeld-Toal
Journal:  Infection       Date:  2017-05-17       Impact factor: 3.553

4.  Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease.

Authors:  M I Thompson; M E Russo; B J Saxon; E Atkin-Thor; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

6.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

7.  The effect of piperacillin dose on elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; M E Brier; F C Luft
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Pharmacokinetics of piperacillin in subjects with various degrees of renal function.

Authors:  P G Welling; W A Craig; R W Bundtzen; F W Kwok; A U Gerber; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

9.  Optimal design of perturbations for individual two-compartment pharmacokinetic analysis.

Authors:  Matthew S Shotwell; Minchun Zhou; William H Fissell
Journal:  J Biopharm Stat       Date:  2015-08-06       Impact factor: 1.051

10.  Piperacillin distribution into bile, gallbladder wall, abdominal skeletal muscle, and adipose tissue in surgical patients.

Authors:  J Russo; M I Thompson; M E Russo; B A Saxon; J M Matsen; F G Moody; L F Rikkers
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.